Kevin Johnson
Partner @ Index Ventures
London, United Kingdom
Kevin Johnson is a seed investor at Index Ventures in London focused on Biotechnology and Medical. Prior to co-founding Medicxi Ventures, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He was formerly on the board of directors of Versartis(Nasdaq: VSAR) and is currently involved with include Acutus and Levicept among others.Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Kevin Johnson invests in
Stages Kevin Johnson invests in
Countries Kevin Johnson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Pharmaceutical 2 (33%)
- Manufacturing 1 (17%)
Stage
- Seed 2 (33%)
- Series A 2 (33%)
- Series B 2 (33%)
Country
- United States 2 (33%)
- Switzerland 1 (17%)
- The Netherlands 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis and polycythemia vera. | $22M / Series A / Oct 13, 2017 | ||
| Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $28M / Series B / Aug 20, 2013 | ||
| Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $44.2M / Series B / Dec 16, 2009 | ||
| Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $15.6M / Series A / Aug 14, 2007 | ||
| PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases.PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employsa lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients | $2M / Seed | ||
| Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $1M / Seed |
Co-Investors
About Index Ventures
Index Ventures is a venture capital company that provides investment capital and strategic support to early-stage and growth-stage technology enterprises across sectors such as software, fintech, healthcare, and consumer services. It engages with entrepreneurial teams to assess business models, support scaling efforts, and provide guidance through successive development phases. The company’s services include sourcing investment opportunities, conducting due diligence, structuring financing deals, and offering ongoing advisory interactions with portfolio founders. Index Ventures also maintains a network of industry relationships and resources aimed at facilitating connections between founders, investors, and market opportunities. Its focus spans from initial seed rounds through later financing stages to help portfolio companies pursue expansion and market entry efforts.
Index Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Georgia Stevenson
Partner
|
|||
Gerald Rimer
Team Member
|
|||
Hannah Seal
Principal/Partner
|
|||
Jan Hammer
Investor & Partner
|
|||
Julia Andre
Principal/Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kevin Johnson invest in?
Kevin Johnson invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kevin Johnson?
Public channels for Kevin Johnson include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kevin Johnson last invest?
The most recent investment recorded for Kevin Johnson closed in Oct 2017. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
